Pharmacy Times

DECEMBER 9, 2023

The efficacy of treatments, which is the outcomes in the ideal clinical trial setting, are known to often be better than the effectiveness of those treatments, which are the outcomes of patients in the real-world setting.

73

73

Fierce Pharma

MARCH 13, 2024

The FDA has raised concerns about early clinical trial deaths as part of two applications that aim to move the CAR-T therapies Carvykti and Abecma into earlier lines of treatment for multiple myelo | Ahead of an important advisory committee meeting, the FDA has raised concerns about early trial deaths for multiple myeloma cell therapies.

FDA 124

FDA 124

PharmaShots

APRIL 10, 2023

Shots: The US FDA has placed a partial clinical hold on the P-I study of MT-0169 in patients with relapsed multiple myeloma. Both the participants completely recovered within 2mos.

FDA 40

FDA Dosage 40

Hospital Pharmacy Europe

AUGUST 24, 2023

Talquetamab has been granted a conditional marketing authorisation by the European Commission as monotherapy for the treatment of adult patients with relapsed and refractory multiple myeloma. Talquetamab clinical efficacy The talquetamab approval was based on efficacy data from the phase 1 and phase 2 MonumenTAL-1 study.

Hospitals 93

Hospitals Dosage Immunization FDA 93

Pharmafile

MARCH 27, 2024

Heidelberg Pharma has announced that it has gained Orphan Drug Designation (ODD) from the US Food and Drug Administration (FDA) for HDP-101 for the treatment of multiple myeloma. The candidate is currently being investigated in a phase 1/2a clinical trial for the treatment of relapsed and refractory multiple myeloma (RRMM).

FDA 59

FDA 59

Hospital Pharmacy Europe

MARCH 13, 2024

A type II variation of ciltacabtagene autoleucel (cilta-cel; brand name Carvykti) has received a positive opinion from the European Medicines Agency (EMA)’s Committee for Medicinal Products for Human Use (CHMP) for use in the treatment of eligible patients with multiple myeloma, its manufacturer Janssen has announced.

Documentation 52

Documentation Hospitals 52

Pharmacy Times

JULY 21, 2023

Multiple myeloma clinical pathways and factors affecting patient quality of life are explored by an expert panel.

123

123

Hospital Pharmacy Europe

JUNE 15, 2023

Selinexor triple therapy with bortezomib and dexamethasone, provides a clinically meaningful improvement in overall survival in lenalidomide-refractory patients with multiple myeloma, according to a study presented at the 2023 European Haematology Association (EHA) Congress. vs 47.2%) and a higher VGPR or better (35.8%

Hospitals 95

Hospitals 95

Fierce Pharma

MARCH 15, 2024

The FDA questioned whether Carvykti should be approved in an earlier line of multiple myeloma after noticing an early detriment to patient survival in a clinical trial. Takeda will shut down a gene therapy manufacturing and R&D facility in Austria. And more.

FDA 98

FDA 98

Fierce Healthcare

OCTOBER 19, 2023

The Mayo Clinic and LifePoint Health believe that collusion within pharmaceutical industry forced their organizations to overpay for the multiple myeloma drug Revlimid, and are petitioning the cour | The health systems said agreements between Revlimid's owners, Celgene and Bristol-Myers Squibb, and other drugmakers that delayed full production (..)

Mayo Clinic 126

Mayo Clinic 126

European Pharmaceutical Review

JANUARY 4, 2024

New research from the US indicates that a prophylactic treatment before immunotherapy can significantly reduce the rate of cytokine release syndrome (CRS) in multiple myeloma patients. The drug tocilizumab for example, has been used historically to treat CRS from immunotherapies.

Immunization 82

Immunization Hospitals FDA 82

European Pharmaceutical Review

AUGUST 10, 2023

The US Food and Drug Administration (FDA) has granted accelerated approval of TALVEY (talquetamab-tgvs) to treat multiple myeloma. Multiple myeloma MonumenTAL-1 study In the dose-escalation MonumenTAL-1 study, which incorporated Phase I and Phase II , over 300 patients were enrolled. A median duration of follow-up of 10.4

Pharmaceutical Companies 98

Pharmaceutical Companies Pharmaceutical Companies FDA 98

Pharmaceutical Technology

FEBRUARY 7, 2024

BCMA-GPRC5D CAR-T Cells is under clinical development by Guangzhou Bio-gene Technology and currently in Phase II for Relapsed Multiple Myeloma.

75

75

Pharmacy Times

OCTOBER 20, 2022

Anderson, PharmD, CSP, clinical program manager at Alliance Rx Walgreens Pharmacy, discusses the impact pharmacists have on the care journey for patients with multiple myeloma.

Clinical Program Management 123

Clinical Program Management 123

Pharmaceutical Technology

FEBRUARY 8, 2024

GEN-3014 is under clinical development by Genmab and currently in Phase II for Relapsed Multiple Myeloma.

75

75

Pharmaceutical Commerce

FEBRUARY 21, 2024

Regeneron Pharmaceuticals’ linvoseltamab is currently in clinical development to treat adult patients with relapsed/refractory multiple myeloma who experienced disease progression following prior administration of at least three therapies.

FDA 59

FDA 59

European Pharmaceutical Review

FEBRUARY 26, 2024

Clinical data showed approximately 60 percent reductions in plasma NfL concentrations in patients given Qalsody compared to placebo. After 12 weeks, patients treated with danicopan had a clinically-relevant increase in haemoglobin (an average of 2.35 This indicated reduced neuronal injury, EMA noted.

Generic Medicine 93

Generic Medicine Pharmaceutical Companies Pharmaceutical Companies Vaccines 93

STAT

FEBRUARY 10, 2023

The CAR-T cancer therapy called Abecma reduced the risk of multiple myeloma relapse by half compared to standard treatment, according to results of a Phase 3 clinical trial published Friday.

98

98

Hospital Pharmacy Europe

AUGUST 24, 2023

Talquetamab has been granted a conditional marketing authorisation by the European Commission as monotherapy for the treatment of adult patients with relapsed and refractory multiple myeloma. The post Talquetamab approved by European Commission for relapsed/refractory multiple myeloma appeared first on Hospital Pharmacy Europe.

Dosage 52

Dosage Hospitals FDA 52

European Pharmaceutical Review

JANUARY 19, 2023

The National Institute for Health and Care Excellence (NICE) has recommended Ninlaro ® (ixazomib) with lenalidomide and dexamethasone for treating relapsed/refractory multiple myeloma (RRMM). It was the first oral proteasome inhibitor to enter Phase III clinical trials and to receive a regulatory approval.

Hospitals 79

Hospitals Documentation 79

Pharmaceutical Technology

APRIL 24, 2023

The National Institute for Health and Care Excellence (NICE) has published a final draft guidance recommending the use of Darzalex (daratumumab) with bortezomib and dexamethasone (DVd) for adults with previously treated multiple myeloma. Myeloma is a treatable but incurable type of bone marrow cancer.

Documentation 98

Documentation 98

pharmaphorum

NOVEMBER 22, 2022

GSK confirmed this morning that the disappointing readout from the DREAMM-3 trial of multiple myeloma therapy Blenrep reported earlier this month means that it will take the drug off the US market. Some patients will be able to continue to receive the drug via a compassionate use programme.

FDA 105

FDA 105

STAT

JANUARY 25, 2024

Gilead needs Arcellx more than ever The clinical trial setback for Trodelvy in non-small cell lung cancer reported by Gilead Sciences on Monday was another dose of bad news for the company’s oncology business. Continue to STAT+ to read the full story…

99

99

Pharmafile

DECEMBER 12, 2022

A new and experimental immunotherapy treatment has appeared successful in treating patients with multiple myeloma in an ongoing phase 1/2 clinical trial. The blood cancer treatment has seen successful response rates in 73% of patients, and an application has been submitted to the FDA to bring the drug to market. read more.

FDA 90

FDA 90

Pharmaceutical Technology

OCTOBER 27, 2023

Eftozanermin alfa is under clinical development by AbbVie and currently in Phase I for Refractory Multiple Myeloma.

52

52

Pharmaceutical Technology

FEBRUARY 7, 2024

BCMA-GPRC5D CAR-T Cells is under clinical development by Guangzhou Bio-gene Technology and currently in Phase II for Refractory Multiple Myeloma.

40

40

Pharmaceutical Technology

DECEMBER 12, 2022

Gilead company Kite has entered an international strategic partnership with Arcellx for the joint development and commercialisation of the latter’s T-cell therapy, CART-ddBCMA, to treat relapsed or refractory multiple myeloma patients. Additionally, Kite will make other potential payments to Arcellx.

Communication 105

Communication 105

European Pharmaceutical Review

NOVEMBER 7, 2022

has announced its B-cell maturation antigen (BCMA)-CD3-targeted bispecific antibody (BsAb) elranatamab for relapsed or refractory multiple myeloma (RRMM) has received Breakthrough Therapy Designation from the US Food and Drug Administration (FDA). Elranatamab clinical trial data. Pfizer Inc. The majority were either Grade 1 (43.2

FDA 99

FDA 99

Pharmaceutical Technology

FEBRUARY 8, 2024

GEN-3014 is under clinical development by Genmab and currently in Phase II for Refractory Multiple Myeloma.

40

40

Pharmaceutical Technology

JANUARY 8, 2024

Subasumstat is under clinical development by Takeda Pharmaceutical and currently in Phase II for Relapsed Multiple Myeloma.

40

40

Pharmaceutical Technology

JANUARY 8, 2024

Subasumstat is under clinical development by Takeda Pharmaceutical and currently in Phase II for Relapsed Multiple Myeloma.

52

52

Pharmaceutical Technology

NOVEMBER 14, 2022

The UK Medicines and Healthcare products Regulatory Agency (MHRA) has granted marketing authorisation for Oncopeptides’ Pepaxti (melphalan flufenamide; melflufen) along with dexamethasone to treat multiple myeloma patients. Pepaxti provides clinical benefit to patients with triple class refractory disease.

52

52

Pharmaceutical Technology

DECEMBER 21, 2023

Enzalutamide is under clinical development by Pfizer and currently in Phase I for Relapsed Multiple Myeloma.

40

40

pharmaphorum

MARCH 15, 2022

Sanofi has agreed a deal with life sciences investor Blackstone to help fund clinical trials of a new formulation of Sarclisa for blood cancer multiple myeloma, accelerating its development. The post Blackstone funds new trials of Sanofi’s Sarclisa in myeloma appeared first on.

97

97

Pharmaceutical Technology

SEPTEMBER 14, 2023

BCMA-GPRC5D CAR-T Cells is under clinical development by Guangzhou Bio-gene Technology and currently in Phase II for Refractory Multiple Myeloma.

40

40

European Pharmaceutical Review

NOVEMBER 7, 2022

The findings will serve as a benchmark for future prospective clinical studies that intend to improve the outcomes of patients who progress after CAR-T.”. “The The findings will serve as a benchmark for future prospective clinical studies that intend to improve the outcomes of patients who progress after CAR-T.”.

Immunization 80

Immunization 80

Pharmaceutical Technology

OCTOBER 27, 2023

Eftozanermin alfa is under clinical development by AbbVie and currently in Phase I for Relapsed Multiple Myeloma.

52

52